However, inhibiting IL-6 signaling to limit cytokine-dependent lung injury, using sarilumab or tocilizumab for example, has only been explored in Covid-19 patients (Rossotti et al., 2020; Sinha et al., 2020), rheumatoid arthritis-related interstitial lung disease (Manfredi et al., 2020; Vacchi et al., 2020), and PAH (Hernandez-Sanchez et al., 2018). The gene discussed is IL6; the disease is pulmonary arterial hypertension.